XOMA Shares Plunge 22.76% Following Phase 3 Study Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Source: Globenewswire
- Significant Stock Drop: XOMA's stock price fell by $7.82, or 22.76%, to close at $25.39 on December 19, 2025, following Rezolute's announcement that its Phase 3 sunRIZE study did not meet its primary endpoint, directly impacting investor confidence and market performance.
- Poor Study Results: Rezolute reported that while there was an approximate 45% reduction in hypoglycemia events at the highest dose of ersodetug, this was not statistically significant compared to the placebo group's 40% improvement, highlighting the limitations of the drug's efficacy.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether XOMA and its executives engaged in securities fraud or other unlawful business practices, which could further impact the company's reputation and future legal liabilities.
- Increased Investor Vigilance: The study failure and subsequent stock drop have heightened investor scrutiny on XOMA's future developments and market strategies, potentially leading to greater challenges in financing and partnerships for the company.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 71.00 USD with a low forecast of 50.00 USD and a high forecast of 97.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.660
Low
50.00
Averages
71.00
High
97.00
Current: 24.660
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Poor Clinical Trial Results: The Phase 3 sunRIZE study results released by Rezolute, Inc. indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, raising concerns about XOMA's future prospects in the market.
- Significant Stock Drop: Following the unfavorable news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 per share on December 19, 2025, reflecting investor disappointment in the company's outlook.
- Increased Legal Risks: As the investigation progresses, XOMA may face heightened legal liabilities and potential compensation claims, which could have long-term negative impacts on the company's financial health and market reputation.
Continue Reading
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- Disappointing Clinical Trial Results: Rezolute, Inc.'s Phase 3 sunRIZE study results indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, potentially impacting XOMA's market outlook.
- Significant Stock Drop: Following the adverse news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, reflecting market pessimism regarding the company's future.
- Increased Legal Risks: As the investigation unfolds, XOMA faces potential legal liabilities and compensation risks, which could adversely affect its financial condition and investor trust in the long term.
Continue Reading